Walmart settles opioid lawsuit with $50 million payment to DOJ

Walmart agreed on Friday to pay $50 million to settle a Department of Justice lawsuit alleging its pharmacies unlawfully filled opioid prescriptions and contributed to the national opioid epidemic. The settlement is substantially smaller than the billions in civil penalties the retailer initially faced when the lawsuit was filed in December 2020. Walmart admitted no wrongdoing in the settlement and characterized the $50 million payment as immaterial in regulatory filings. Federal prosecutors had alleged the company violated the Controlled Substances Act since 2013 by ignoring red flags on suspicious prescriptions, with some compliance staff apparently aware that certain prescribers operated pill mills. The settlement represents another step in the broader enforcement effort against opioid distribution across the supply chain, following larger settlements by other pharmacies and distributors.

1. Walmart agreed to pay $50 million to settle DOJ allegations that its pharmacies unlawfully filled opioid prescriptions.
2. The settlement amount is a fraction of the billions in civil penalties Walmart faced when the suit was filed in December 2020.
3. Walmart admitted no wrongdoing and called the payout immaterial in a regulatory filing.
4. Federal prosecutors alleged Walmart violated the Controlled Substances Act since 2013 by ignoring red flags on suspicious prescriptions.
5. The settlement was announced on August 29, 2026.
6. Walmart reported second-quarter revenue of $187.94 billion and adjusted earnings per share of $0.81, beating consensus estimates.